Breast cancer patients with positive HR status (HR+) are suggested to receive endocrine therapy, and patients with positive HER2 status (HER2+) are suggested to receive HER2-targeted therapy, according to the 2021 ASCO guideline for optimized neoadjuvant therapy [2]. The gene discussed is ERBB2; the disease is breast carcinoma.